Skip to search formSkip to main contentSkip to account menu

SB 715992

Known as: SB-715992, SB715992 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

ispinesib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Pediatric phase I trial and pharmacokinetic (PK) study of ispinesib (SB715992): A Children’s Oncology Group phase I consortium study
10014 Background: Ispinesib is a highly specific inhibitor of kinesin spindle protein (KSP), a member of the kinesin superfamily… 
2008
2008
A Phase I Study of the Kinesin Spindle Protein Inhibitor Ispinesib (SB-715992) in Relapsed/Refractory Acute Leukemia
Background. Ispinesib is a novel polycylic, nitrogen-containing heterocycle small molecule that acts by inhibition of the mitotic… 
2007
2007
A phase II, open-label study of ispinesib (SB-715992) in patients with platinum/taxane refractory or resistant relapsed ovarian cancer
5562 Background: Kinesin spindle protein (KSP) is required for mitotic spindle bipolarity and cell cycle progression. Ispinesib… 
2007
2007
University of Chicago Consortium phase II study of ispinesib (SB-715992) in patients (pts) with advanced renal cell carcinoma (RCC)
15573 Background: Ispinesib is a novel kinesin spindle protein inhibitor that has significant antitumor activity in multiple… 
2006
2006
A phase I dose escalation trial of ispinesib (SB-715992) administered days 1-3 of a 21-day cycle in patients with advanced solid tumors.
2026 Background: Ispinesib, a novel cytotoxic agent inhibiting the kinesin spindle protein (KSP) has demonstrated significant… 
2006
2006
Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors.
2027 Background: Kinesin spindle protein (KSP) is required for establishment of mitotic spindle bipolarity and cell cycle… 
2006
2006
640 POSTER Phase I study of ispinesib (SB-715992), a kinesin spindle protein inhibitor, in combination with capecitabine in patients with advanced solid tumors
2004
2004
Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days.
2004 Background: The mitotic kinesin KSP plays an exclusive and essential role in assembly and function of the mitotic spindle… 
2004
2004
Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days.
2078 Background: The mitotic kinesin KSP plays an exclusive and essential role in assembly and function of the mitotic spindle… 
2003
2003
570 A phase I study to determine the safety and pharmacokinetics of intravenous administration of SB715992 on a once weekly for three consecutive weeks schedule in patients with refractory solid…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)